Edison Pharmaceuticals, Inc. Signs Licensing Agreement With Dainippon Sumitomo Pharma Co., Ltd. for Up to $545 Million
3/28/2013 7:35:41 AM
More...
|
Edison Pharmaceuticals, Inc. & Bambino Gesu Children's Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2/19/2013 9:45:54 AM
More...
|
Edison Pharmaceuticals, Inc. Announces Initiation of EPI-743 Phase 2B Friedreich's Ataxia Clinical Trial
1/7/2013 9:55:22 AM
More...
|
Edison Pharmaceuticals, Inc. Closes $20 Million Series F Financing
11/26/2012 10:32:45 AM
More...
|
Edison Pharmaceuticals, Inc. Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
11/13/2012 9:39:23 AM
More...
|
Edison Pharmaceuticals, Inc. Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
9/13/2012 9:47:57 AM
More...
|
European Medicines Agency Grants Orphan Designation to Edison Pharmaceuticals, Inc. for EPI-743 for Treatment of Leigh Syndrome
9/12/2012 11:21:24 AM
More...
|
Edison Pharmaceuticals, Inc. Closes Financing
9/13/2011 11:09:59 AM
More...
|
Edison Pharmaceuticals, Inc. Announces Results of EPI-A0001 Phase 2A Double Blind Placebo Controlled 28-Day Clinical Trial in the Mitochondrial Disease- Friedreich's Ataxia
6/13/2011 6:29:12 AM
More...
|
Edison Pharmaceuticals, Inc. to Provide Expanded Access to EPI-743 for Mitochondrial Disease
6/8/2011 6:59:53 AM
More...
|
|